Loading...

Acura Pharmaceuticals, Inc.

ACUR•PNK
Healthcare
Drug Manufacturers - Specialty & Generic
$0.00
$-0.00(-0.00%)

Acura Pharmaceuticals, Inc. (ACUR) Stock Overview

Explore Acura Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.8/100

Key Financials

Market Cap13.2K
P/E Ratio0.00
EPS (TTM)$-0.02
ROE0.00%
Fundamental Analysis

AI Price Forecasts

1 Week$0.01
1 Month$-0.01
3 Months$0.00
1 Year Target$0.00

ACUR Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Acura Pharmaceuticals, Inc. (ACUR) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 21.18, suggesting the stock is in an oversold condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 0.00 and a market capitalization of 13.2K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

21.18RSI (14)
0.00MACD
92.15ADX
Stats data is not available for ACURStats details for ACUR are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ACURAnalyst Recommendations details for ACUR are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was incorporated in 1935 and is based in Palatine, Illinois.

CEO

Robert B. Jones

Employees

9

Headquarters

616 N. North Court, Palatine, IL

Founded

1986

Frequently Asked Questions

;